On 12 Nov 2026 MetLife closed at $101.87, +32.6% this year; market cap $65.19bn, P/E 12.7.
Financials · Life & Health Insurance · NYSE · United States
MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates in six segments: Group Benefits; Retirement and Income Solutions; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, paid family and medical leave, individual disability, accidental death and dismemberment, accident and health, vision, and pet insurance, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it offers fixed, indexed-linked, and variable annuities; pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity and funded reinsurance solutions; credit insurance products; accident & health products covering hospitalization, cancer, critical illness, income protection, and scheduled medical reimbursement plans; and protection against long-term health care services. The company was incorporated in 1999 and is based in New York, New York.
| Market cap | $65.19bn |
| P/E (trailing) | 12.7 |
| EPS (TTM) | $8.01 |
| Beta | 0.77 |
| Dividend | $2.37 |
| Dividend yield | 2.33% |
| Ex-dividend date | 3 Nov 2026 |
| Latest report | 4 Nov 2026 |
| Next earnings | 3 Feb 2027 |
| YTD | +32.6% |
| 1Y | +30.5% |
| 3Y | +22.5% |
| 5Y | +13.0% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $77.08bn | $3.38bn | $18.11bn |
| 2024 | $70.98bn | $4.43bn | $15.12bn |
| 2023 | $67.71bn | $1.58bn | $14.26bn |
| 2022 | $67.97bn | $5.28bn | $13.20bn |
| 2021 | $63.37bn | $6.86bn | $16.96bn |
We publish no single base value for MetLife. Our valuation methods put it between $108.44 and $879.04 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.